Infertility and Teratogenicity After Paternal Exposure to Systemic Dermatologic Medications: A Systematic Review

This study investigated paternal drug exposure using FDA data and identified significant associations with reproductive health risks, including congenital anomalies linked to immunosuppressive drugs, and emphasized specific risk combinations like biologics and abortion, diazepam and small for date baby, and finasteride and cryptorchidism.

This review explores the impact of various medications on male fertility, highlighting reversible negative effects from methotrexate, finasteride, and ketoconazole, while reporting no adverse fertility effects for oral retinoids and certain immunosuppressants.

This review of the Motherisk Program's counseling experience found a scarcity of information on medication safety related to paternal exposure to drugs and chemicals during the peri-conception period, emphasizing the need for further research.

This review summarizes existing literature on the safety of commonly used dermatologic medications during pregnancy but does not present new clinical findings, aiming to assist physicians with prescribing decisions.

This study observed that male fetuses exposed to finasteride in utero may develop external genital anomalies, with the outcome dependent on the timing of exposure.